Northern Trust’s Pacific Biosciences PACB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $3.95M | Buy |
2,352,786
+221,998
| +10% | +$323K | ﹤0.01% | 2750 |
|
|
2026
Q1 | $2.81M | Buy |
2,130,788
+83,949
| +4% | +$150K | ﹤0.01% | 2788 |
|
|
2025
Q4 | $3.83M | Sell |
2,046,839
-242,057
| -11% | -$465K | ﹤0.01% | 2626 |
|
|
2025
Q3 | $2.93M | Buy |
2,288,896
+82,803
| +4% | +$112K | ﹤0.01% | 2821 |
|
|
2025
Q2 | $2.74M | Sell |
2,206,093
-228,596
| -9% | -$264K | ﹤0.01% | 2813 |
|
|
2025
Q1 | $2.87M | Sell |
2,434,689
-80,135
| -3% | -$123K | ﹤0.01% | 2721 |
|
|
2024
Q4 | $4.6M | Buy |
2,514,824
+157,145
| +7% | +$307K | ﹤0.01% | 2550 |
|
|
2024
Q3 | $4.01M | Sell |
2,357,679
-146,597
| -6% | -$241K | ﹤0.01% | 2607 |
|
|
2024
Q2 | $3.43M | Sell |
2,504,276
-38,621
| -2% | -$78K | ﹤0.01% | 2607 |
|
|
2024
Q1 | $9.54M | Sell |
2,542,897
-154,796
| -6% | -$906K | ﹤0.01% | 2071 |
|
|
2023
Q4 | $26.5M | Sell |
2,697,693
-121,072
| -4% | -$990K | ﹤0.01% | 1419 |
|
|
2023
Q3 | $23.5M | Buy |
2,818,765
+3,004
| +0.1% | +$34.3K | ﹤0.01% | 1438 |
|
|
2023
Q2 | $37.4M | Buy |
2,815,761
+276,619
| +11% | +$3.36M | 0.01% | 1162 |
|
|
2023
Q1 | $29.4M | Buy |
2,539,142
+140,999
| +6% | +$1.4M | 0.01% | 1300 |
|
|
2022
Q4 | $19.6M | Sell |
2,398,143
-15,933
| -0.7% | -$137K | ﹤0.01% | 1535 |
|
|
2022
Q3 | $14M | Buy |
2,414,076
+294,991
| +14% | +$1.69M | ﹤0.01% | 1736 |
|
|
2022
Q2 | $9.37M | Buy |
2,119,085
+139,317
| +7% | +$847K | ﹤0.01% | 2081 |
|
|
2022
Q1 | $18M | Sell |
1,979,768
-4,190
| -0.2% | -$48.2K | ﹤0.01% | 1756 |
|
|
2021
Q4 | $40.6M | Sell |
1,983,958
-318,587
| -14% | -$7.69M | 0.01% | 1264 |
|
|
2021
Q3 | $58.8M | Sell |
2,302,545
-44,413
| -2% | -$1.32M | 0.01% | 960 |
|
|
2021
Q2 | $82.1M | Buy |
2,346,958
+278,659
| +13% | +$8.1M | 0.01% | 778 |
|
|
2021
Q1 | $68.9M | Sell |
2,068,299
-55,839
| -3% | -$1.95M | 0.01% | 879 |
|
|
2020
Q4 | $55.1M | Buy |
2,124,138
+49,337
| +2% | +$838K | 0.01% | 997 |
|
|
2020
Q3 | $20.5M | Buy |
2,074,801
+164,625
| +9% | +$948K | ﹤0.01% | 1608 |
|
|
2020
Q2 | $6.59M | Buy |
1,910,176
+108,371
| +6% | +$369K | ﹤0.01% | 2354 |
|
|
2020
Q1 | $5.51M | Buy |
1,801,805
+27,194
| +2% | +$111K | ﹤0.01% | 2245 |
|
|
2019
Q4 | $9.12M | Sell |
1,774,611
-56,013
| -3% | -$285K | ﹤0.01% | 2234 |
|
|
2019
Q3 | $9.45M | Buy |
1,830,624
+74,029
| +4% | +$414K | ﹤0.01% | 2184 |
|
|
2019
Q2 | $10.6M | Buy |
1,756,595
+13,290
| +0.8% | +$93.2K | ﹤0.01% | 2116 |
|
|
2019
Q1 | $12.6M | Buy |
1,743,305
+55,777
| +3% | +$403K | ﹤0.01% | 1999 |
|
|
2018
Q4 | $12.5M | Buy |
1,687,528
+161,208
| +11% | +$1.02M | ﹤0.01% | 1922 |
|
|
2018
Q3 | $8.26M | Buy |
1,526,320
+63,090
| +4% | +$271K | ﹤0.01% | 2372 |
|
|
2018
Q2 | $5.2M | Buy |
1,463,230
+140,090
| +11% | +$389K | ﹤0.01% | 2664 |
|
|
2018
Q1 | $2.71M | Buy |
1,323,140
+118,214
| +10% | +$307K | ﹤0.01% | 2952 |
|
|
2017
Q4 | $3.18M | Sell |
1,204,926
-57,029
| -5% | -$200K | ﹤0.01% | 2870 |
|
|
2017
Q3 | $6.63M | Buy |
1,261,955
+185,895
| +17% | +$799K | ﹤0.01% | 2453 |
|
|
2017
Q2 | $3.83M | Buy |
1,076,060
+84,795
| +9% | +$342K | ﹤0.01% | 2780 |
|
|
2017
Q1 | $5.13M | Buy |
991,265
+28,744
| +3% | +$141K | ﹤0.01% | 2542 |
|
|
2016
Q4 | $3.66M | Buy |
962,521
+29,097
| +3% | +$211K | ﹤0.01% | 2755 |
|
|
2016
Q3 | $8.36M | Buy |
933,424
+42,464
| +5% | +$355K | ﹤0.01% | 2194 |
|
|
2016
Q2 | $6.27M | Buy |
890,960
+136,970
| +18% | +$1.25M | ﹤0.01% | 2317 |
|
|
2016
Q1 | $6.41M | Buy |
753,990
+62,065
| +9% | +$610K | ﹤0.01% | 2262 |
|
|
2015
Q4 | $9.09M | Buy |
691,925
+36,357
| +6% | +$326K | ﹤0.01% | 2082 |
|
|
2015
Q3 | $2.4M | Buy |
655,568
+13,999
| +2% | +$68.4K | ﹤0.01% | 2933 |
|
|
2015
Q2 | $3.69M | Buy |
641,569
+26,032
| +4% | +$151K | ﹤0.01% | 2709 |
|
|
2015
Q1 | $3.59M | Buy |
615,537
+3,935
| +0.6% | +$27.1K | ﹤0.01% | 2719 |
|
|
2014
Q4 | $4.79M | Sell |
611,602
-4,326
| -0.7% | -$27.7K | ﹤0.01% | 2532 |
|
|
2014
Q3 | $3.02M | Buy |
615,928
+58,078
| +10% | +$304K | ﹤0.01% | 2833 |
|
|
2014
Q2 | $3.45M | Sell |
557,850
-35,647
| -6% | -$178K | ﹤0.01% | 2770 |
|
|
2014
Q1 | $3.17M | Sell |
593,497
-46,751
| -7% | -$295K | ﹤0.01% | 2853 |
|
|
2013
Q4 | $3.35M | Buy |
640,248
+25,252
| +4% | +$116K | ﹤0.01% | 2834 |
|
|
2013
Q3 | $3.4M | Buy |
614,996
+111,737
| +22% | +$388K | ﹤0.01% | 2758 |
|
|
2013
Q2 | $1.27M | Buy |
+503,259
| New | +$1.25M | ﹤0.01% | 3201 |
|
Other funds holding PACB
AIM
NAMA
Northern Trust's PACB Position: Q2 2026 in Review
Northern Trust increased its Pacific Biosciences (PACB) stake by 10% in Q2 2026, buying an estimated $323K and bringing the position to 2,352,786 shares worth $3.95M. The position accounts for ﹤0.01% of the portfolio, ranked #2750.
Northern Trust first reported a position in PACB in Q2 2013 and has held it in 53 quarters since. The position peaked at $82.1M in Q2 2021. 223 funds tracked by Wall St. Rank hold PACB as of Q2 2026.
- Northern Trust held 2,352,786 shares of Pacific Biosciences worth $3.95M as of Q2 2026.
- Northern Trust bought 221,998 Pacific Biosciences shares in Q2 2026, an estimated $323K.
- Pacific Biosciences made up ﹤0.01% of Northern Trust's portfolio in Q2 2026, its #2750 holding.
- Northern Trust first reported a position in Pacific Biosciences in Q2 2013 and has held it in 53 quarters since.
- Northern Trust's Pacific Biosciences position peaked at $82.1M in Q2 2021.
- 223 funds tracked by Wall St. Rank held Pacific Biosciences as of Q2 2026.
Based on Northern Trust's 13F filing for Q2 2026, filed 13 Aug 2026.